What are the effects of omega-3 fatty acids, specifically EPA and EPA+DHA, on fatal and non-fatal cardiovascular outcomes?
Omega-3 EPA/DHA Fish Oil, a systematic review and meta-analysis in 149,051 participants (EClinicalMedicine 2021, PMID 34505026) — EPA monotherapy showed greater reductions for cardiovascular mortality (RR, 0.82), non-fatal MI (RR, 0.72), and CHD events (RR, 0.73) compared to EPA+DHA (cardiovascular mortality RR, 0.94. The abstract states 'None' for limitations.
Source: EClinicalMedicine 2021, PMID 34505026 ↗ · Research map · How Magellan grades evidence · evidence confidence: high
EClinicalMedicine · 2021 · PMID 34505026 · DOI 10.1016/j.eclinm.2021.100997
Omega-3 fatty acids reduce cardiovascular risks, with EPA monotherapy showing greater benefits but also increased risks of bleeding and atrial fibrillation.
The question
What are the effects of omega-3 fatty acids, specifically EPA and EPA+DHA, on fatal and non-fatal cardiovascular outcomes?
What they tested
The study aimed to determine the effectiveness of omega-3 FAs on cardiovascular outcomes and examine potential variability between EPA monotherapy and EPA+DHA therapy.
How they did it
A meta-analysis of 38 randomized controlled trials was conducted, including 149,051 participants. The trials were stratified by EPA monotherapy and EPA+DHA therapy. Random-effects rate ratios (RRs) with 95% confidence intervals were estimated, and the certainty of evidence was rated using GRADE. Key outcomes included cardiovascular mortality, non-fatal cardiovascular outcomes, bleeding, and atrial fibrillation (AF).
What they found
Omega-3 FAs were associated with reductions in cardiovascular mortality (RR, 0.93), non-fatal myocardial infarction (MI) (RR, 0.87), coronary heart disease events (CHD) (RR, 0.91), major adverse cardiovascular events (MACE) (RR, 0.95), and revascularization (RR, 0.91). EPA monotherapy showed greater reductions for cardiovascular mortality (RR, 0.82), non-fatal MI (RR, 0.72), and CHD events (RR, 0.73) compared to EPA+DHA (cardiovascular mortality RR, 0.94; non-fatal MI RR, 0.92; CHD events RR, 0.94). Omega-3 FAs increased incident AF (RR, 1.26), and EPA monotherapy was associated with a higher risk of total bleeding (RR, 1.49) and AF (RR, 1.35).
| Cardiovascular Mortality (Overall) | 0.93 | |
|---|---|---|
| Non-fatal MI (Overall) | 0.87 | |
| CHD Events (Overall) | 0.91 | |
| MACE (Overall) | 0.95 | |
| Revascularization (Overall) | 0.91 | |
| Incident AF (Overall) | 1.26 | |
| Cardiovascular Mortality (EPA) | 0.82 | |
| Cardiovascular Mortality (EPA+DHA) | 0.94 | |
| Non-fatal MI (EPA) | 0.72 | |
| Non-fatal MI (EPA+DHA) | 0.92 | |
| CHD Events (EPA) | 0.73 | |
| CHD Events (EPA+DHA) | 0.94 | |
| Total Bleeding (EPA) | 1.49 | |
| AF (EPA) | 1.35 |
Rate ratios for various cardiovascular outcomes, showing overall effects of omega-3 FAs and stratified effects for EPA monotherapy versus EPA+DHA therapy.
What it means
Omega-3 fatty acids reduced cardiovascular mortality and improved cardiovascular outcomes. The cardiovascular risk reduction was more prominent with EPA monotherapy than with EPA+DHA.
Limitations
The abstract states 'None' for limitations.
The paper at a glance
| Title | Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis |
|---|---|
| Journal | EClinicalMedicine |
| Year | 2021 |
| PMID | 34505026 ↗ |
| DOI | 10.1016/j.eclinm.2021.100997 ↗ |
| Topic | Cardiovascular & vascular aging |
Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗
Where Magellan uses this paper
This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.
Omega-3 EPA/DHA Fish Oil
Across large randomized trials and meta-analyses, marine omega-3s reliably reduce serum triglycerides (roughly 15% at higher doses) and modestly lower blood pressure and resting heart rate, but their effect on cardiovascular events is mixed and depends on dose, formulation and population.
Omega-3 fatty acids are long-chain polyunsaturated fats, principally eicosapentaenoic acid (EPA) and…
Research describes the compound or intervention studied. It is not a claim about any specific product.
Molecules & mechanisms in this paper
Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.
Cite this page
These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.
Magellan Longevity. (2026). What are the effects of omega-3 fatty acids, specifically EPA and EPA+DHA, on fatal and non-fatal cardiovascular outcomes? [Plain-English summary of EClinicalMedicine 2021, PMID 34505026, DOI 10.1016/j.eclinm.2021.100997]. Magellan Longevity. https://magellanlongevity.com/study/d34505026.html@misc{magellan_d34505026,
title = {What are the effects of omega-3 fatty acids, specifically EPA and EPA+DHA, on fatal and non-fatal cardiovascular outcomes?},
author = {{Magellan Longevity}},
year = {2026},
howpublished = {\url{https://magellanlongevity.com/study/d34505026.html}},
note = {Plain-English summary of PubMed PMID 34505026; DOI 10.1016/j.eclinm.2021.100997; EClinicalMedicine 2021. Reviewed by Gabriel Radu, DO},
urldate = {2026-08-11}
}https://magellanlongevity.com/study/d34505026.htmlRelated studies in the Magellan library
- Effect of Omega-3 Dosage on Cardiovascular Outcomes: An Updated Meta-Analysis of…Mayo Clin Proc · 2020 · PMID 32951855
- What are the effects of increased intake of fish- and plant-based omega-3 fats (LCn3 and ALA)…Cochrane Database Syst Rev · 2020 · PMID 32114706
- Omega-3 fatty acids and mortality in patients referred for coronary angiographyAtherosclerosis · 2016 · PMID 27397734
- What is the significance of the erythrocyte EPA+DHA percentage (Omega-3 Index) for brain…Nutrients · 2021 · PMID 33806218
- Potential Modulation of Inflammation by Probiotic and Omega-3 Supplementation in Elderly with…Nutrients · 2022 · PMID 36235651
- Impact of dietary nitrate supplementation on exercise capacity and cardiovascular parametersBMJ Open Respiratory Research · 2021 · PMID 34489239
All 67 Magellan summaries on cardiovascular & vascular aging →
Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →